Anvisa board appointment highlights Brazilian hot topics
This article was originally published in Clinica
Jaime César de Moura Oliveira has joined the four-member directorship of Brazil’s healthcare regulatory agency, Anvisa. Mr Oliveira enters the agency with a background that includes ministerial legal support roles and his areas of expertise are bioethics, biosecurity and environmental law. His appointment was approved by the Senate’s social affairs committee during a meeting to discuss the regulatory themes he was most interested in. The themes included: the importance of cultivating the agency’s public consultations process as the means of ensuring the best adoption of Anvisa’s policies and guidance; and the war on clandestine and counterfeit healthcare products.
You may also be interested in...
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.
Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex
T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.